<DOC>
	<DOCNO>NCT03066011</DOCNO>
	<brief_summary>The purpose study describe representative real-world pattern care management invasive fungal infection ( IFIs ) , include invasive mold infection ( IMI ) . Specifically , study goal examine real world patient characteristic treatment pattern , associate healthcare resource utilization , outcomes associate use mold-active triazoles ( MATs ) treat invasive fungal infection ( IFIs ) .</brief_summary>
	<brief_title>Registry Patients Treated With Systemic Mold-Active Triazoles</brief_title>
	<detailed_description />
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>Patients initiate one follow target drug : isavuconazonium sulfate ( ISAV ) , voriconazole ( VORI ) , posaconazole ( POSA ) . Patients may enrol within 60 day time treatment initiation . Currently enrol clinical trial investigational antifungal agent . Individuals subsequently enroll investigational antifungal study discontinue data collect time investigational product evaluable . Retrospective patient die enter study . Patients previously participate registry .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>mold-active triazoles</keyword>
</DOC>